LOUVAIN-LA-NEUVE, BELGIUM, AND KRAKOW, POLAND, November 15, 2016 – IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions, announces the first patient treatment at the Bronowice Cyclotron Center Institute of Nuclear Physics in Krakow, Poland, on November 3rd. The patient was treated in a 360°full gantry treatment room with the most precise technique of Pencil Beam Scanning. The treatment of the patient from the Institute of Oncology, Krakow, was performed by joint teams from the Institute of Oncology Krakow and the Henryk Niewodniczanski Institute of Nuclear Physics.

The center is equipped with a Proteus®PLUS* solution comprising two-gantry rooms, including its most advanced Pencil Beam Scanning capabilities allowing the delivery of Intensity Modulated Proton Therapy, and a dedicated research room for advanced proton research activities. The project has been developed and delivered in three phases to the specific needs of Institute of Nuclear Physics of Krakow. With its extensive experience in proton therapy, IBA has delivered the expansion of the center without any interruption to the ongoing activities in the previously accepted rooms.

The Krakow center has already had experience with proton therapy and particularly treatment of the eye melanoma using its own in-house technology. Today, with IBA's most advanced technology, the center can now target the full range of indications for proton therapy.

Professor Jezabek, General Director of the Institute of Nuclear Physics in Krakow, said: "One of the most important elements of the choice of IBA was the unique expertise the company has in the field of proton therapy and its contribution to advanced technologies related to the cyclotron during the last years."

Manoj Sahasrabudhe, IBA's Chief Operating Officer, Proton Therapy, commented on this achievement: "We are pleased to report further use of our proton therapy solution and the enthusiasm of the radiation oncology community in Krakow and the surrounding regions. It is an honor for IBA to collaborate with the prestigious Polish Academy of Sciences in the fight against cancer in Europe and making proton therapy accessible to the oncology patients from Poland."

* Proteus®PLUS is the brand name of a Proteus®235.


About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

About the Bronowice Cyclotron Centre
The Bronowice Cyclotron Centre (in Polish - Centrum Cyklotronowe Bronowice, CCB) is a part of the Henryk Niewodniczañski Institute of Nuclear Physics Polish Academy of Sciences in Krakow (IFJ PAN). We are engaged in the application of cyclotrons in scientific research and tumour radiotherapy.

The following activities are being conducted in CCB:
- experiments in nuclear physics, medical physics, dosimetry, microdosimetry, radiobiology and materials engineering,
- production of radionuclides for research purposes,
- development of clinical and scientific infrastructure intended for a non-invasive tumour treatment.

At CCB two cyclotrons are presently in operation:
- AIC-144 isochronous cyclotron
- Proteus C230 cyclotron